ArticleNeurologic clinics2011
Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.
Article in Neurologic clinics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- The epidemiology and phenomenology of non-antipsychotic-induced dystonia: a hybrid systematic-narrative review.European psychiatry : the journal of the Association of European Psychiatrists · 2025Pooled it
- Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis.JAMA network open · 2024Pooled it
- Tardive dyskinesia in Asia- current clinical practice and the role of neurologists in the care pathway.Frontiers in neurology · 2024Pooled it
- Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies.PloS one · 2021Pooled it
- Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.CNS drugs · 2019Pooled it
- Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis.Schizophrenia bulletin · 2018Pooled it
- Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis.CNS drugs · 2016Pooled it
- Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review.The American journal of orthopsychiatry · 2016Pooled it
- Ziprasidone versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2009Pooled it
- Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS.Clinical drug investigation · 2021Trial
- Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.Journal of neurology, neurosurgery, and psychiatry · 2019Trial
- Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.Neurology · 2017Trial
- A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics.Journal of pediatric endocrinology & metabolism : JPEM · 2011Trial
- The mechanism underlying tardive dyskinesia: an exploratory test of the dopamine overactivity hypothesis using MRI imaging of midbrain neuromelanin.Psychopharmacology · 2026Article
- Budget impact of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the United States.Journal of managed care & specialty pharmacy · 2026Article
- Neurological Adverse Effects of Antipsychotic Medication in Children and Young People.Paediatric drugs · 2026Review
- Emerging non-DFrontiers in psychiatry · 2026Review
- Exploring the Role of Oral Microbiota in the Pathophysiology and Treatment of Bruxism.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Review
- Detailing Healthcare Claims Data Evidence of Extrapyramidal Symptoms in Medicaid Patients with Schizophrenia after Second-Generation Antipsychotic Medication Initiation.Community mental health journal · 2025Article
- Mutism and rigidity due to antipsychotic-induced catatonia improved by hemodialysis: A case report.PCN reports : psychiatry and clinical neurosciences · 2025Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Drug-induced movement disorders have dramatically declined with the widespread use of second-generation antipsychotics, but remain important in clinical practice and for understanding antipsychotic pharmacology. The diagnosis and management of dystonia, parkinsonism, akathisia, catatonia, neuroleptic malignant syndrome, and tardive dyskinesia are reviewed in relation to the decreased liability of the second-generation antipsychotics contrasted with evidence from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. Data from the CATIE trial imply that advantages of second-generation antipsychotics in significantly reducing extrapyramidal side effects compared with haloperidol may be diminished when compared with modest doses of lower-potency first-generation drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.